Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, a clinical-stage biopharmaceutical company focused on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, has announced new employee inducement awards. On October 1, 2024, the company granted restricted stock units (RSUs) representing 16,400 shares of its common stock to two newly-hired non-executive employees.
The grants were approved by the Compensation Committee of Fate Therapeutics' Board of Directors under the company's Amended and Restated Inducement Equity Plan. These RSUs will vest over four years, with 25% of the shares vesting on each anniversary of the grant date, contingent on continuous employment. The awards comply with Nasdaq Listing Rule 5635(c)(4) as an inducement for new employees joining the company.
Fate Therapeutics, una società biofarmaceutica in fase clinica focalizzata sullo sviluppo di immunoterapie cellulari derivate da iPSC per il cancro e le malattie autoimmuni, ha annunciato nuovi premi per l'induzione dei dipendenti. Il 1 ottobre 2024, l'azienda ha concesso unità azionarie ristrette (RSU) rappresentanti 16.400 azioni del suo capitale sociale a due nuovi dipendenti non esecutivi.
Le concessioni sono state approvate dal Comitato per le Retribuzioni del Consiglio di Amministrazione di Fate Therapeutics nell'ambito del Piano di Induzione Azionaria Modificato e Ripristinato. Queste RSU matureranno in quattro anni, con il 25% delle azioni che matura ogni anniversario della data di concessione, subordinato all'impiego continuativo. I premi sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4) come indennizzo per i nuovi dipendenti che si uniscono all'azienda.
Fate Therapeutics, una empresa biofarmacéutica en etapa clínica enfocada en el desarrollo de inmunoterapias celulares derivadas de iPSC para el cáncer y enfermedades autoinmunes, ha anunciado nuevos premios de inducimiento para empleados. El 1 de octubre de 2024, la compañía otorgó unidades de acciones restringidas (RSUs) que representan 16,400 acciones de sus acciones ordinarias a dos nuevos empleados no ejecutivos.
Las concesiones fueron aprobadas por el Comité de Compensación de la Junta Directiva de Fate Therapeutics bajo el Plan de Inducción de Capital Modificado y Restablecido de la empresa. Estas RSUs se consolidarán en cuatro años, con el 25% de las acciones consolidándose en cada aniversario de la fecha de concesión, dependiendo del empleo continuo. Los premios cumplen con la Regla de Cotización de Nasdaq 5635(c)(4) como inducimiento para los nuevos empleados que se unen a la compañía.
Fate Therapeutics는 임상 단계의 생명공학 회사로, 암 및 자가면역 질환을 위한 iPSC 유래 세포 면역 요법 개발에 집중하고 있으며, 새로운 직원 유인 보상을 발표했습니다. 2024년 10월 1일에 이 회사는 두 명의 신입 비임원 직원에게 16,400주의 보통주를 나타내는 제한 주식 단위(RSU)를 부여했습니다.
이 보상은 Fate Therapeutics의 이사회 보상 위원회의 승인을 받았으며, 회사의 수정된 유인 지분 계획에 따라 진행되었습니다. 이 RSU는 4년에 걸쳐 체결됩니다, 부여일의 매주년에 25%의 주식이 체결되며, 지속적인 고용을 조건으로 합니다. 이 보상은 새로운 직원이 회사에 합류할 때 유인책으로 Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.
Fate Therapeutics, une entreprise biopharmaceutique en phase clinique axée sur le développement d'immunothérapies cellulaires dérivées de iPSC pour le cancer et les maladies auto-immunes, a annoncé de nouvelles primes d'incitation aux employés. Le 1er octobre 2024, la société a accordé des unités d'actions restreintes (RSU) représentant 16 400 actions de ses actions ordinaires à deux nouveaux employés non exécutifs.
Ces attributions ont été approuvées par le Comité de Rémunération du Conseil d'Administration de Fate Therapeutics dans le cadre du Plan d'Équité d'Induction Modifié et Restitué de l'entreprise. Ces RSU seront acquises sur quatre ans, avec 25 % des actions acquises chaque année à la date anniversaire de la concession, sous réserve de l'emploi continu. Les attributions respectent la Règle de Cotation Nasdaq 5635(c)(4) en tant qu'incitation pour les nouveaux employés rejoignant l'entreprise.
Fate Therapeutics, ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von iPSC-abgeleiteten Zelltherapien für Krebs und Autoimmunerkrankungen konzentriert, hat neue Anreizzahlungen für Mitarbeiter angekündigt. Am 1. Oktober 2024 gewährte das Unternehmen beschränkte Aktieneinheiten (RSUs), die 16.400 Aktien seines Stammkapitals repräsentieren, an zwei neu eingestellte nicht-executive Mitarbeiter.
Die Zuwendungen wurden vom Vergütungsausschuss des Verwaltungsrats von Fate Therapeutics im Rahmen des Änderungen und Ergänzungen des Induktions-Eigenkapitalplans genehmigt. Diese RSUs werden über vier Jahre fällig, wobei 25 % der Aktien an jedem Jubiläum des Zuwendungsdatums fällig werden, vorausgesetzt, die Beschäftigung bleibt bestehen. Die Auszeichnungen entsprechen der Nasdaq-Listingregel 5635(c)(4) als Anreiz für neue Mitarbeiter, die dem Unternehmen beitreten.
- Attraction of new talent to support company growth
- Implementation of employee retention strategy through equity-based compensation
- None.
SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2024 the Company granted restricted stock units (RSUs) representing 16,400 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
How many shares of restricted stock units (RSUs) did Fate Therapeutics grant to new employees on October 1, 2024?
What is the vesting schedule for the RSUs granted by Fate Therapeutics (FATE) to new employees?
Under which plan were the new employee inducement awards granted by Fate Therapeutics (FATE)?
What Nasdaq rule does Fate Therapeutics' (FATE) new employee inducement awards comply with?
